<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01316302</url>
  </required_header>
  <id_info>
    <org_study_id>PF2010SAD</org_study_id>
    <secondary_id>WS1228302</secondary_id>
    <nct_id>NCT01316302</nct_id>
  </id_info>
  <brief_title>12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder</brief_title>
  <official_title>A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Pristiq® (Desvenlafaxine) Extended-Release Tablets in Generalized Social Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medical Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Medical Research Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of Pristiq® in treatment of the
      symptoms of Generalized Social Anxiety Disorder (SAD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Social Anxiety Disorder (SAD) is recognized as a prevalent, chronic and disabling condition.
      Lifetime prevalence has been estimated at 13% in the National Comorbidity Survey. There is
      good reason to think that Pristiq® would be effective in Social Anxiety Disorder. Effexor XR,
      which is mechanistically similar to Pristiq®, was found effective for subjects with
      Generalized Social Anxiety Disorder in all five of the placebo controlled trials in which it
      was studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Liebowitz Social Anxiety Scale (LSAS) Total Score</measure>
    <time_frame>Baseline to study endpoint (Week 12)</time_frame>
    <description>Liebowitz Social Anxiety Scale, measuring social anxiety symptoms; possible total scores ranging from 0-144, with higher scores indicating greater severity of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement Scale (CGI-I)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>CGI-I: one item, measuring overall improvement of illness; possible scores range from 1-7, with lower scores representing greater improvement. CGI-I responders: defined as having a CGI-I scores of 1 or 2 at Week 12/study endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>Baseline to study endpoint (Week 12)</time_frame>
    <description>Subject-rated global outcome scale. Subjects who rated themselves as 1 (Very Much Improved) or 2 (Much Improved) on the PGIC were considered self-rated responders.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Social Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Pristiq</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flexible dose, 50-100mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pristiq</intervention_name>
    <description>Flexible dose, 50-100mg QD, for 12 weeks.</description>
    <arm_group_label>Pristiq</arm_group_label>
    <other_name>desvenlafaxine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo, taken QD for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must give written informed consent prior to any study procedures.

          -  Diagnosis of Social Anxiety Disorder (SAD) (300.23 Social Phobia/Social Anxiety
             Disorder, Generalized Subtype) according to DSM-IV-TR criteria, as determined by
             psychiatric evaluation with the Principal Investigator.

          -  A minimum score of 60 on the LSAS total score at both Screening and Baseline visits.

          -  A total HAM-D score of less than 15 at the Screening visit.

          -  CGI Severity score of 4 or greater at both Screening and Baseline visits.

          -  Female subjects of childbearing potential must commit to an effective form of
             contraception for the duration of the trial. Effective forms of contraception include:
             condoms with spermicide, diaphragm with spermicide, hormonal contraceptive agents
             (oral, transdermal, or injectable), and implantable contraceptive devices.

        Exclusion Criteria:

          -  An Axis I disorder other than SAD (e.g., post-traumatic stress disorder, obsessive
             compulsive disorder, panic disorder) within 24 weeks of the Baseline visit. Subjects
             with co-morbid MDD, GAD, dysthymia, or specific phobias will be allowed if GSAD is the
             primary disorder in terms of clinical severity, as determined by the investigator.

          -  Any history or complication of schizophrenia or bipolar disorder.

          -  Any complication of body dysmorphic disorder.

          -  Substance dependence, as defined by DSM-IV-TR criteria, within 24 weeks of the
             Baseline visit.

          -  Subjects who are currently pregnant, lactating, or of childbearing potential and not
             practicing an effective method of contraception.

          -  Subjects scoring &gt;2 on item #3 of the HAM-D, or who, in the opinion of the PI, are at
             a clinically significant risk for suicide.

          -  Systolic blood pressure ≥165 and/or diastolic blood pressure ≥95.

          -  Positive Urine Drug Screen at the Screening visit.

          -  Any current unstable and/or clinically significant medical condition, based on history
             or as evidenced in Screening laboratory and ECG assessments.

          -  Any history or complication of cancer or malignant tumor.

          -  Fluoxetine within 28 days of Baseline

          -  MAO inhibitors within 14 days of Baseline - Any other psychotropics (including SSRIs,
             SNRIs, and benzodiazepines) within 14 days of Baseline. Zolpidem (Ambien®) PRN is
             allowed for insomnia if not taken more than 3 times per week.

          -  Subjects who started psychotherapy or cognitive-behavioral therapy within 24 weeks of
             the Baseline visit, except for supportive psychotherapy.

          -  Electro-convulsive therapy (ECT) within 12 weeks of the Baseline visit.

          -  Treatment refractory GSAD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R. Liebowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Medical Research Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Medical Research Network, LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.MedicalResearchNetwork.com</url>
    <description>Click here for more information about The Medical Research Network.</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2011</study_first_posted>
  <results_first_submitted>September 30, 2014</results_first_submitted>
  <results_first_submitted_qc>October 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 8, 2014</results_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Social Anxiety Disorder</keyword>
  <keyword>Social Phobia</keyword>
  <keyword>SAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pristiq</title>
          <description>Flexible dose, 50-100mg QD
Pristiq: Flexible dose, 50-100mg QD, for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo
Placebo: Matching placebo, taken QD for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pristiq</title>
          <description>Flexible dose, 50-100mg QD
Pristiq: Flexible dose, 50-100mg QD, for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo
Placebo: Matching placebo, taken QD for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.9" spread="14.6"/>
                    <measurement group_id="B2" value="41.9" spread="13.7"/>
                    <measurement group_id="B3" value="40.0" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Liebowitz Social Anxiety Scale (LSAS) Total Score</title>
        <description>Liebowitz Social Anxiety Scale, measuring social anxiety symptoms; possible total scores ranging from 0-144, with higher scores indicating greater severity of symptoms.</description>
        <time_frame>Baseline to study endpoint (Week 12)</time_frame>
        <population>The number of participants for analysis was 29 subjects per arm; data analyzed at Week 12 or Last Observation Carried Forward for the 16 subjects who dropped out before completion. Five other randomized subjects (1 on drug, 4 on placebo) were excluded from the ITT sample because of insufficient data (n = 4) or poor compliance (n = 1).</population>
        <group_list>
          <group group_id="O1">
            <title>Pristiq</title>
            <description>Flexible dose, 50-100mg QD
Pristiq: Flexible dose, 50-100mg QD, for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo
Placebo: Matching placebo, taken QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Liebowitz Social Anxiety Scale (LSAS) Total Score</title>
          <description>Liebowitz Social Anxiety Scale, measuring social anxiety symptoms; possible total scores ranging from 0-144, with higher scores indicating greater severity of symptoms.</description>
          <population>The number of participants for analysis was 29 subjects per arm; data analyzed at Week 12 or Last Observation Carried Forward for the 16 subjects who dropped out before completion. Five other randomized subjects (1 on drug, 4 on placebo) were excluded from the ITT sample because of insufficient data (n = 4) or poor compliance (n = 1).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean baseline LSAS total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" spread="17.1"/>
                    <measurement group_id="O2" value="92.1" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint LSAS total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" spread="27.4"/>
                    <measurement group_id="O2" value="63.4" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean LSAS change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4" spread="28.8"/>
                    <measurement group_id="O2" value="28.7" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Improvement Scale (CGI-I)</title>
        <description>CGI-I: one item, measuring overall improvement of illness; possible scores range from 1-7, with lower scores representing greater improvement. CGI-I responders: defined as having a CGI-I scores of 1 or 2 at Week 12/study endpoint.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pristiq</title>
            <description>Flexible dose, 50-100mg QD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Improvement Scale (CGI-I)</title>
          <description>CGI-I: one item, measuring overall improvement of illness; possible scores range from 1-7, with lower scores representing greater improvement. CGI-I responders: defined as having a CGI-I scores of 1 or 2 at Week 12/study endpoint.</description>
          <units>% of subjects who were CGI-I responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Change</title>
        <description>Subject-rated global outcome scale. Subjects who rated themselves as 1 (Very Much Improved) or 2 (Much Improved) on the PGIC were considered self-rated responders.</description>
        <time_frame>Baseline to study endpoint (Week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pristiq</title>
            <description>Flexible dose, 50-100mg QD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Change</title>
          <description>Subject-rated global outcome scale. Subjects who rated themselves as 1 (Very Much Improved) or 2 (Much Improved) on the PGIC were considered self-rated responders.</description>
          <units>percentage of self-rated responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8"/>
                    <measurement group_id="O2" value="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pristiq</title>
          <description>Flexible dose, 50-100mg QD
Pristiq: Flexible dose, 50-100mg QD, for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo
Placebo: Matching placebo, taken QD for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>.06</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>indigestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness/lightheadedness/feeling faint</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>nausea/queasiness</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>flu/flu symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>soft stools/diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael R. Liebowitz, M.D.</name_or_title>
      <organization>The Medical Research Network, LLC</organization>
      <phone>(212) 595-5012</phone>
      <email>MLiebowitz@MedicalResearchNetwork.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

